Wegovy Canada: Cost, Availability, and How it Compares to Ozempic

If you’ve been researching weight loss medications in Canada, you’ve likely come across both Wegovy and Ozempic. The two are closely related, as each contains the same active ingredient — semaglutide. However, Wegovy and Ozempic are not the same treatment.

Wegovy is the version of semaglutide that’s actually approved by Health Canada for weight management. Ozempic, on the other hand, is only officially approved for use in people with Type 2 Diabetes. Another important difference is that Wegovy can be used at a higher dose than Ozempic, which may result in higher weight loss.

In this article, we’ll cover everything you need to know about Wegovy in Canada, including how it works, how much it costs, insurance coverage, side effects, and when generic alternatives may become available. We also go into detail about the key differences between Ozempic vs Wegovy.

What Is Wegovy?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable medication manufactured by Novo Nordisk. It belongs to a class of drugs called GLP-1 receptor agonists, which work by mimicking a hormone your body naturally produces to regulate appetite and blood sugar.

Unlike Ozempic, which is approved in Canada exclusively for Type 2 diabetes, Wegovy is specifically approved for chronic weight management in adults with a BMI of 30 or greater (obesity), or a BMI of 27 or greater with at least one weight-related health condition. Wegovy is also approved for cardiovascular risk reduction in people with established heart disease, and as a standalone treatment for a severe liver disease known as MASH (metabolic dysfunction-associated steatohepatitis).

In Canada, Wegovy is delivered using a multi-dose FlexTouch pen. Unlike the single-use auto-injectors available in the United States, the Canadian Wegovy pen operates identically to the Ozempic pen. Patients attach a new needle each week, dial the pen to their prescribed dose, and press a button to inject. One pen contains a four-week supply of the medication.

How Does Wegovy Work for Weight Loss?

Wegovy works through the same mechanisms as other semaglutide-based GLP-1 medications. If you’ve already read our guide to Ozempic, the science will be familiar, but here’s a brief overview.

Semaglutide (the key ingredient of Wegovy) mimics the GLP-1 hormone, which your body releases naturally after eating. GLP-1 plays several roles in appetite regulation, including:

• Slowing gastric emptying (meaning food stays in your stomach longer after a meal, helping you feel full).
• Acting on appetite centres in the brain to reduce hunger.
• Enhancing insulin secretion to help regulate blood sugar.

Many people taking Wegovy describe a noticeable reduction in what’s sometimes called “food noise” — the persistent background thoughts about food and eating that can make weight management so difficult. By addressing these biological drivers of overeating, Wegovy helps people eat less without constantly fighting food cravings.

How Much Weight Can You Lose on Wegovy?

The clinical evidence for Wegovy comes primarily from the STEP trial program, which was a series of large, randomized, placebo-controlled studies.

In the foundational STEP 1 trial, 1,961 adults without diabetes took Wegovy or a placebo for 68 weeks alongside lifestyle changes. The results were significant: participants on Wegovy lost an average of 14.9% of their body weight (compared to just 2.4% for those on placebo). In practical terms, that’s an average loss of roughly 15 kg (33 lbs).

Looking at specific weight loss outcomes from STEP 1:

• Approximately 86% of patients lost at least 5% of their body weight
• 69% lost at least 10% of their body weight
• About half lost 15% or more
• Roughly one in three participants lost at least 20% of their body weight

The impressive thing is that these results are comparable to some bariatric surgery outcomes, which had long been considered the most effective medically-assisted weight loss treatment.

Do the Weight Loss Results from Wegovy Last?

A common concern with weight loss medications is whether the results hold up over time. The STEP 5 trial addressed this directly by following patients being treated with Wegovy for two full years. The trial found that 104 weeks after starting treatment, participants on Wegovy maintained an average weight loss of 15.2% of their original body weight.

However, obesity is a chronic metabolic condition, and research shows that stopping GLP-1 medications like Wegovy, Ozempic and Mounjaro can lead to significant weight regain. 

Weight Regain After Stopping Wegovy

In the STEP 1 Extension trial, researchers followed patients for a full year after they stopped taking Wegovy. They found that participants regained an average of two-thirds of their prior weight loss within 12 months of stopping the medication, and their cardiovascular improvements also reverted toward baseline.

A recent comprehensive 2026 meta-analysis confirmed these findings. While the study looked at a wide range of weight loss medications, it found that patients who stopped taking newer GLP-1s like Wegovy regained weight at a rate of about 0.8 kg (1.8 lbs) per month, projecting a return to their starting weight within 1.5 to 2 years. 

These findings support the medical consensus that Wegovy is designed as a long-term therapy, and also highlight the importance of having a comprehensive lifestyle change and maintenance plan in place.

Wegovy and Heart Health: The SELECT Trial

Perhaps the most important clinical development for Wegovy is the SELECT trial — a landmark study that goes beyond weight loss entirely.

The SELECT trial enrolled over 17,600 adults across 41 countries. These were non-diabetic patients who were overweight or obese and had established cardiovascular disease (such as a prior heart attack, stroke, or peripheral artery disease). 

Over an average follow-up of nearly 40 months, participants on Wegovy experienced a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo.

Potential Benefits of Wegovy Beyond Weight Loss 

The SELECT trial findings are particularly notable because the cardiovascular benefits appeared early in the trial, before participants had achieved their maximum weight loss. 

A major October 2025 follow-up analysis by University College London found that the reduction in heart attacks and strokes occurred regardless of a patient’s starting weight or how much weight they lost during the trial. Researchers concluded that roughly two-thirds of Wegovy’s cardiovascular benefits are driven by direct cardioprotective and anti-inflammatory effects, rather than just the reduction in body fat.

Implications for Insurance Coverage

The SELECT trial results have significantly shifted the Canadian insurance landscape.

Back in 2022, Canada’s Drug Agency (CDA-AMC) initially recommended against public reimbursement for Wegovy, citing a lack of data on long-term health outcomes. However, based on the strength of the SELECT trial, the agency reversed its stance in July 2025. 

The CDA-AMC now officially recommends that public drug plans reimburse Wegovy for patients with a BMI of 27 or greater who also have established cardiovascular disease. This is currently putting immense pressure on provincial health ministries to add Wegovy to their public formularies for this high-risk group.

Wegovy vs Ozempic

Since both medications contain semaglutide, the Ozempic vs Wegovy question comes up frequently. Here are the key differences.

• Approved use: Ozempic is approved in Canada for Type 2 diabetes. Wegovy in Canada is approved for chronic weight management and cardiovascular risk reduction. While many people use Ozempic off-label for weight loss, Wegovy was specifically designed, dosed, and approved for that purpose.
• Dosing: Ozempic’s maximum maintenance dose is 2.0 mg per week. Wegovy goes up to 2.4 mg, which clinical trials show produces greater average weight loss (roughly 15% of body weight vs 10-12% with Ozempic’s lower doses).
• Pen design: In Wegovy Canada and Ozempic pens, there is actually no difference in pen design. Both medications use a multi-dose FlexTouch pen where the patient manually attaches a needle, dials their prescribed dose, and presses a button to inject. (Note: If you are researching online, you may see Wegovy described as a single-use “hidden needle” autoinjector. That specific pen is only distributed in the United States).
• Cost: As of early 2026, brand-name Wegovy typically costs more per month than Ozempic at most Canadian pharmacies. Out-of-pocket, Ozempic generally costs between $250 to $300 per month, while Wegovy ranges from $400 to $570. However, generic versions of semaglutide are currently under Health Canada review and are expected to significantly lower these costs by mid-late 2026.

Taking the above into consideration, if you’re currently using Ozempic off-label for weight loss in Canada, it may be worth speaking with your doctor about whether Wegovy is a more appropriate option.

How Much Does Wegovy Cost in Canada?

Cost is one of the most common concerns for Canadians considering Wegovy. Because this is a long-term medication, understanding Wegovy price and coverage options is essential for your planning.

Wegovy Cost Without Insurance

If you do not have private insurance coverage, the retail price for a one-month supply of brand-name Wegovy (one multi-dose FlexTouch pen containing four weekly doses) typically ranges from $400 to $570.

The final price you pay for Wegovy can vary based on:

• Pharmacy dispensing fees: These usually add around $10 to $15 per fill.
• Province of residence: While the manufacturer’s base price is consistent, slight variations in wholesale markups exist across Canada.
• Dosage: Most Canadian pharmacies maintain consistent pricing across all Wegovy strengths (from the 0.25 mg starting dose up to the 2.4 mg maintenance dose), though it is always best to confirm before your first fill.

Note: These prices are approximate and may vary. We recommend confirming current pricing directly with your pharmacy.

Is Wegovy Covered by Insurance in Canada?

The only way to know for sure if Wegovy is covered by your insurance is to check with your provincial drug plan or private insurer. However, below are some general guidelines around what to expect.

Private insurance

Coverage for Wegovy is expanding, but is not yet universal. Most major private insurers now have established pathways to cover Wegovy.

However, almost all private plans require Prior Authorization (PA). To be approved, your prescribing doctor usually needs to submit a standardized PA form confirming:

1. A qualifying BMI (typically 30+, or 27+ with a weight-related condition).
2. A history of previous weight management attempts.
3. Evidence that you are using the medication alongside lifestyle changes (diet and exercise).

With successful private coverage, out-of-pocket copays can drop significantly, sometimes to as little as $25 to $100 per month.

Provincial Drug Plans

Historically, provincial drug plans (such as ODB in Ontario or BC PharmaCare) have not covered Wegovy for general weight management. However, a major shift occurred in July 2025, when Canada’s Drug Agency (CDA-AMC) issued a landmark recommendation. 

CDA-AMC advised that public plans should reimburse Wegovy for adults with a BMI of 27 or greater who also have established cardiovascular disease. Provincial health ministries are currently updating their formularies to reflect this, meaning public coverage for high-risk patients is becoming more common.

Generic Wegovy in Canada

For many Canadians, the most significant development on the cost front is the arrival of generic semaglutide (the active ingredient of Wegovy). Following the expiry of key patents on January 4, 2026, Health Canada is currently reviewing multiple applications for generic semaglutide from manufacturers like Sandoz, Apotex, and Teva.

• Timeline: The first generic versions are expected to reach Canadian pharmacy shelves by mid-to-late 2026.
• Price Drop: Standard Canadian generic pricing models suggest that once multiple competitors enter the market, the cost could drop to roughly 35% of the brand-name price.

This transition could potentially bring the monthly cost of Wegovy treatment down to under $150, making this medication accessible to millions more Canadians who currently find it financially out of reach.

Wegovy Dosing Schedule

Wegovy uses a gradual dose escalation over 16 weeks to help your body adjust and minimise side effects. The official dosing schedule works as follows:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

Each dosage level comes in its own colour-coded multi-dose pen (which contains a full four-week supply), so there’s no risk of confusion as you move up in strength.

Inject Wegovy subcutaneously (under the skin) in your abdomen, thigh, or upper arm, and rotate the injection site each week. You can take your weekly dose on any day, at any time, with or without food.

What to Do If You Miss a Wegovy Dose

If you miss a dose of Wegovy, take it as soon as you remember — provided it is within 5 days of when the dose was due (meaning your next scheduled dose is more than 48 hours away). If more than 5 days have passed, skip the missed dose and simply resume your regular schedule on your normal day.

Important Safety Note: If you miss more than two consecutive weeks of Wegovy, do not attempt to take your regular high dose. You should speak with your healthcare provider, as you may need to restart at the lowest 0.25 mg dose to avoid side effects.

Side Effects of Wegovy

Like all GLP-1 receptor agonists, Wegovy’s most common side effects are gastrointestinal. In the STEP clinical trials, the most frequently reported issues were:

• Nausea (affecting approximately 44% of patients)
• Diarrhea (30%)
• Vomiting (25%)
• Constipation (24%)

These numbers can sound concerning at first glance, but context matters. 

The majority of Wegovy side effects are mild to moderate, and they tend to peak during the dose escalation phase (particularly when moving up to a new dose level). Most patients find that symptoms improve significantly once they’ve been on the 2.4 mg maintenance dose for a few weeks. 

Tips for Managing Wegovy Side Effects

To reduce the likelihood of gastrointestinal discomfort, consider eating smaller, more frequent meals rather than large ones, avoiding greasy, fried, or heavily spiced foods (especially during dose increases), staying well hydrated, and eating slowly. These are the same strategies recommended for patients on Ozempic and Mounjaro.

Who Should Not Take Wegovy?

Wegovy is not suitable for everyone. You should not take it if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a history of severe pancreatitis, active gallbladder disease, or severe gastroparesis (since the medication naturally slows stomach emptying).

Pregnancy Warning: You should not take Wegovy if you are pregnant or breastfeeding. Because the medication has a long half-life, Health Canada explicitly directs patients to stop taking Wegovy at least two months before a planned pregnancy.

Your doctor will typically order baseline bloodwork — including HbA1c, a lipid panel, renal function tests, and pancreatic enzyme levels — before starting Wegovy to ensure the medication is safe for you.

Wegovy Pill in Canada

If you’ve searched for “Wegovy pill Canada,” you may be aware that an oral tablet version of Wegovy has been developed. Novo Nordisk launched oral Wegovy in the United States in early 2026, offering daily tablets in strengths up to 25 mg. Clinical trial data (from the OASIS 4 trial) showed that the 25 mg oral tablet produced roughly 17% average weight loss at 64 weeks — comparable to the injectable version.

However, as of early 2026, the oral Wegovy tablet is not yet approved by Health Canada. While Novo Nordisk is expected to seek Canadian regulatory approval following its successful US launch, the once-weekly injectable pen remains the only format of Wegovy legally authorized and available in Canada.

It’s worth noting that the Wegovy pill requires strict fasting protocols — it must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait before eating or drinking anything else. For Canadians interested in an oral GLP-1 that doesn’t require fasting, Orforglipron is a promising alternative currently in clinical trials, with potential Health Canada approval expected in late 2026 or early 2027.

Frequently Asked Questions About Wegovy

Is Wegovy available in Canada?

Yes. Wegovy has been approved by Health Canada and is available by prescription at Canadian pharmacies. However, supply can fluctuate depending on demand, so check with your pharmacy about current availability.

How much does Wegovy cost per month in Canada?

Without insurance, Wegovy in Canada typically costs between $400 and $570 per month at retail pharmacies, though lower pricing may be available through select providers. With private insurance coverage, copays can range from approximately $25 to $100 per month depending on your plan.

How much is Wegovy in Canada without insurance?

The out-of-pocket cost for Wegovy without insurance is generally $400 to $570 per month. Bulk purchasing (three-month supplies) through online pharmacies may bring the per-month cost closer to $400. Generic semaglutide, expected in mid-to-late 2026, could reduce this significantly.

When will generic Wegovy be available in Canada?

Data exclusivity and core semaglutide patents expired in Canada in early 2026, and several generic manufacturers have submitted applications to Health Canada. The first generic products are projected to reach pharmacies in mid-to-late 2026, pending regulatory approval.

Is Wegovy covered by insurance in Canada?

Private insurance plans increasingly cover Wegovy with prior authorization, though coverage varies by plan. While provincial drug plans have historically not covered Wegovy for general weight management, a recent CDA-AMC recommendation is paving the way for expanded public coverage for patients with cardiovascular disease.

What’s the difference between Wegovy and Ozempic?

Both contain the active ingredient semaglutide and use the exact same multi-dose FlexTouch pen in Canada. The main differences are that Wegovy in Canada is specifically approved for weight management at a higher maximum dose (2.4 mg vs. 2.0 mg) and has clinical data proving it reduces cardiovascular events, whereas Ozempic is only approved for Type 2 diabetes.

Wegovy Canada — Is It Right for You?

Wegovy represents a significant step forward in medically supported weight management for Canadians. With strong clinical evidence showing sustained weight loss of approximately 15%, cardiovascular benefits for high-risk patients, and the prospect of more affordable generic alternatives arriving later in 2026, it’s becoming an increasingly accessible option.

That said, Wegovy in Canada is a prescription medication that requires medical supervision, baseline bloodwork, and a gradual dose escalation over several months. It works best as part of a comprehensive plan that includes dietary changes and physical activity — not as a standalone solution.

If you’re considering Wegovy or want to discuss whether it’s the right fit for your situation, speaking with a healthcare provider is the best first step. At Walk In, Canadian-licensed doctors are available for virtual consultations to assess your needs and discuss your weight management options from the comfort of your home.

Speak With a Virtual Doctor About Weight Loss Treatment